Uwe Weisner

April 12, 2021

As General Manager Corporate Intellectual Property at Volkswagen AG in Wolfsburg, Germany, Uwe is responsible for filing, prosecuting, licensing and enforcing Volkswagen’s Patents, Trademarks, Design Rights, Internet-Domains and defending against third party IP claims. In addition, he is responsible for standardization. Prior, Uwe served more than 15 years as a Patent Manager for Volkswagen AG and Audi AG, also located in Germany. Further functions: Chairman of the IP Committee of VDA (German Association of Automotive Industry), Board Member of the IP Committee of BDI (Association of German Industries) and Board Member of VPP (Association of Industry Patent Professionals in Germany). From 2010 to 2017 Lecturer at the Technical University of Braunschweig for “Business Practice of Intellectual Property.”

Dr. Walter C. Copan – Congressional Testimony: The State of U.S. Science and Technology: Ensuring U.S. Global Leadership

February 11, 2025
On February 5th, 2025, Dr. Walter C. Copan testified before the House Committee on Science, Space, and Technology on the State of U.S. Science and Technology: Ensuring U.S. Global Leadership. Copan, Vice President for Research and Technology Transfer at the Colorado School of Mines, former Director of the National Institute
Read More

(Transcript) Protecting Intellectual Property for National Security: A Conversation with Rep. Nathaniel Moran (R-TX)

December 4, 2024
This transcript is from a CSIS and LeadershIP event hosted on December 3, 2024. Watch the full video here. John J. Hamre: Good afternoon, everybody. Welcome. We’re delighted to have you here. My name is John Hamre. I’m the president at CSIS. And this is going to be one
Read More

Generic Drugs, Property Rights, and the Orange Book

December 4, 2024
By Chris Borges Intellectual property (IP) rights secured through patents facilitate the introduction of dozens of new brand-name drugs and hundreds of generic drugs annually in the United States. However, proposals advanced by the Biden administration have mistakenly singled out patents as the cause of high drug prices, potentially harming the dense networks
Read More